<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-123052</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Advances in arterial hypertension and diabetes mellitus</dc:title>
<dc:description xml:lang="en">In 2011, the importance of hypertension and diabetes mellitus as the two main risk factors responsible for the development of cardiovascular disease became clear, as did their significance as major public health issues. Compared with previous years, in which publication of the results of large clinical trials dominated scientific progress, in the last year, the focus has shifted to evidence that novel mechanisms associated with blood pressure, glucose metabolism and diabetes can influence cardiovascular disease. Of particular importance were clinical trials in the area of renal dysfunction, such as the SHARP and ROADMAP tri (AU)</dc:description>
<dc:creator>Cordero, Alberto</dc:creator>
<dc:creator>Lekuona, Iñaki</dc:creator>
<dc:creator>Galve, Enrique</dc:creator>
<dc:creator>Mazón, Pilar</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En 2011 ha quedado patente la relevancia de la hipertensión arterial y la diabetes mellitus como los dos principales factores de riesgo implicados en el desarrollo de la enfermedad cardiovascular y, además, un problema de salud pública de primer orden. En comparación con años anteriores, en los que la publicación de grandes ensayos clínicos copó las principales novedades científicas, este último año ha destacado la evidencia del impacto de nuevos mecanismos relacionados con la presión arterial, el metabolismo de la glucosa y la diabetes mellitus en la enfermedad cardiovascular, y sobresalen ensayos clínicos en el ámbito de la disfunción renal, como los estudios SHARP o ROADMAP (AU)</dc:description>
<dc:source>Rev Esp Cardiol;65(supl.1): 12-23, 2012. ilus, tab</dc:source>
<dc:identifier>ibc-123052</dc:identifier>
<dc:title xml:lang="es">Novedades en hipertensión arterial y diabetes mellitus</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d50495^s22032</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7152^s22012</dc:subject>
<dc:subject>^d7182^s22073</dc:subject>
<dc:subject>^d3942</dc:subject>
<dc:subject>^d962^s22073</dc:subject>
<dc:subject>^d2359^s22027</dc:subject>
<dc:type>article</dc:type>
<dc:date>201200</dc:date>
</metadata>
</record>
</ibecs-document>
